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Abstract:  Post-transplant  lymphoproliferative
complication  of  solid  organ  transplantation  or,  more  rarely,  hematopoietic  stem  cell 
transplantation. The majority of PTLD is of B
virus  (EBV) infection. PTLD generally d
histology  and  aggressive  clinical  behavior.  The  molecular  pathogenesis  of  PTLD  involves 
infection by oncogenic viruses, namely 
several cellular genes. At variance with lymphoma arising in immunocompetent hosts, whose 
genome is relatively stable, a fraction of PTLD are characterized by microsatellite instability 
as  a  consequence  of  defects  in  the  DNA  mismatch  repair  mechanism.  Apart  from 
microsatellite instability, molecular alterations of cellular genes recognized in PTLD include 
alterations  of  cMYC,  BCL6,  TP53,  DNA  hypermethylation,  and  aberrant  somatic 
hypermutation of protooncogenes. The occurrence of IGV  mutations in the overwhelming 
majority of PTLD documents that malignant transformation targets germinal centre (GC) B
cells  and  their  descendants  both  in  EBV
phenotypic markers of B-cell histogenesis, namely BCL6, MUM1 and CD138, allows further 
distinction of PTLD histogenetic categories. PTLD expressing the BCL6+/MUM1+/
profile reflect B-cells actively experiencing the GC reaction, and comprise diffuse large B
lymphoma  (DLBCL)  centroblastic  and  Burkitt  lymphoma.  PTLD  expressing  the  BCL6
/MUM1+/CD138- phenotype  putatively  derive  from  B
reaction,  and  comprise  the  majority  of  polymorphic  PTLD  and  a  fraction  of  DLBCL 
immunoblastic.  A  third  group  of  PTLD  is  reminiscent  of  post
differentiated  B-cells that  show  the  BCL6
morphologically represented by either polymorphic PTLD or DLBCL immunoblastic.
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transplant  lymphoproliferative disorders  (PTLD)  are  a  life
complication  of  solid  organ  transplantation  or,  more  rarely,  hematopoietic  stem  cell 
transplantation. The majority of PTLD is of B-cell origin and associated with Epstein
virus  (EBV) infection. PTLD generally display  involvement of  extranodal  sites, aggressive 
histology  and  aggressive  clinical  behavior.  The  molecular  pathogenesis  of  PTLD  involves 
infection by oncogenic viruses, namely EBV, as well as genetic or epigenetic alterations of 
t variance with lymphoma arising in immunocompetent hosts, whose 
genome is relatively stable, a fraction of PTLD are characterized by microsatellite instability 
as  a  consequence  of  defects  in  the  DNA  mismatch  repair  mechanism.  Apart  from 
tability, molecular alterations of cellular genes recognized in PTLD include 
alterations  of  cMYC,  BCL6,  TP53,  DNA  hypermethylation,  and  aberrant  somatic 
hypermutation of protooncogenes. The occurrence of IGV  mutations in the overwhelming 
ocuments that malignant transformation targets germinal centre (GC) B
cells  and  their  descendants  both  in  EBV–positive  and  EBV–negative  cases.  Analysis  of 
cell histogenesis, namely BCL6, MUM1 and CD138, allows further 
PTLD histogenetic categories. PTLD expressing the BCL6+/MUM1+/
cells actively experiencing the GC reaction, and comprise diffuse large B
lymphoma  (DLBCL)  centroblastic  and  Burkitt  lymphoma.  PTLD  expressing  the  BCL6
phenotype  putatively  derive  from  B-cells  that  have  concluded  the  GC 
reaction,  and  comprise  the  majority  of  polymorphic  PTLD  and  a  fraction  of  DLBCL 
immunoblastic.  A  third  group  of  PTLD  is  reminiscent  of  post-GC  and  preterminally 
that  show  the  BCL6-/MUM1+/CD138+  phenotype,  and  are 
morphologically represented by either polymorphic PTLD or DLBCL immunoblastic.
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disorders  (PTLD)  are  a  life-threatening 
complication  of  solid  organ  transplantation  or,  more  rarely,  hematopoietic  stem  cell 
cell origin and associated with Epstein–Barr 
isplay  involvement of  extranodal  sites, aggressive 
histology  and  aggressive  clinical  behavior.  The  molecular  pathogenesis  of  PTLD  involves 
, as well as genetic or epigenetic alterations of 
t variance with lymphoma arising in immunocompetent hosts, whose 
genome is relatively stable, a fraction of PTLD are characterized by microsatellite instability 
as  a  consequence  of  defects  in  the  DNA  mismatch  repair  mechanism.  Apart  from 
tability, molecular alterations of cellular genes recognized in PTLD include 
alterations  of  cMYC,  BCL6,  TP53,  DNA  hypermethylation,  and  aberrant  somatic 
hypermutation of protooncogenes. The occurrence of IGV  mutations in the overwhelming 
ocuments that malignant transformation targets germinal centre (GC) B-
negative  cases.  Analysis  of 
cell histogenesis, namely BCL6, MUM1 and CD138, allows further 
PTLD histogenetic categories. PTLD expressing the BCL6+/MUM1+/-/CD138-
cells actively experiencing the GC reaction, and comprise diffuse large B-cell 
lymphoma  (DLBCL)  centroblastic  and  Burkitt  lymphoma.  PTLD  expressing  the  BCL6-
cells  that  have  concluded  the  GC 
reaction,  and  comprise  the  majority  of  polymorphic  PTLD  and  a  fraction  of  DLBCL 
GC  and  preterminally 
/MUM1+/CD138+  phenotype,  and  are 
morphologically represented by either polymorphic PTLD or DLBCL immunoblastic.Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Introduction: Post-transplant lympho-proliferative 
disorder  (PTLD)  is  one  of  the  most  serious 
complications  of  immunosuppression  in  patients 
undergoing  both  solid  organ  and  hematopoietic 
stem  cell  (HSC)  transplantation,  contributing 
significantly  to  morbidity  and  mortality  in  this 
group  of  patients
1-4. PTLD  encompass  a 
heterogeneous  group  of  lymphoproliferative 
diseases,  ranging  from  reactive,  polyclonal 
hyperplasia,  to  highly  aggressive  monomorphic 
proliferations which may be indistinguishable from 
aggressive  lymphomas
5,6.  According  to  the  WHO 
classification
7,  PTLD  may  be  classified  into:  (i) 
early lesions, generally represented by EBV driven 
polyclonal  lymphoproliferations,  and  (ii)  true 
monoclonal diseases, including polymorphic PTLD 
(P-PTLD)  and  monomorphic  PTLD;  the  latter 
further distinguished into Burkitt lymphoma (BL), 
diffuse  large  B-cell  lymphoma  (DLBCL)  and 
Hodgkin lymphoma (Figure 1). 
There is a known relationship between Epstein 
Barr Virus (EBV) and PTLD, given that the EBV 
genome is found in approximately 80% of PTLD 
specimens
8,9. In  these  cases,  the  pathogenesis  of 
PTLD  is  associated  with  the  uncontrolled 
proliferation of EBV infected B-cells in the absence 
of EBV-specific cellular immune response
9. PTLD 
are, however, not exclusively associated with EBV 
infection,  as  EBV-negative  PTLD,  with  a 
preference to develop late after transplantation, are 
frequently reported
10-12.
The  risk  of  developing  PTLD  varies  greatly, 
depending upon the type of transplanted organ, the 
patient’s  age  at  transplantation,  and  the  immune-
suppressive  regimen used.  In  HSC  transplant 
recipients,  the  incidence  of  PTLD  is  0.5%  after 
HLA-matched noncomplicated transplants and 25% 
after  T-cell-depleted  highly  immunesuppressed 
transplants
13. In  the  case  of  solid  organ 
transplantation, the overall incidence of PTLD is 1–
5%
14-16. The disease arises in 1–5% kidney and liver 
transplant  recipients,  5–15%  heart  and  heart-lung 
transplant patients, and 10–15% intestinal transplant 
recipients
14-16. PTLD  occur  more  commonly  in 
pediatric  patients  than  in  adults
17.  The  higher 
incidence in children is thought to result from the 
fact  that  they  have  a  greater  likelihood  of  being 
EBV-naïve  recipients  of EBV-seropositive  graft
17. 
PTLD is observed more frequently in the first year 
following  transplantation,  when  the  recipient  is 
more severely  immunocompromised.  However, as 
the  prognosis  improves  for  individuals  receiving 
solid  organ  transplant,  a  long-term risk  of  PTLD 
development  late  after  transplantation  is 
increasingly recognized
11,12,14-16.
PTLD  share  several  features  with  other 
immunodeficiency-related  lymphomas
5-7. These 
common  features  include  a  preferential 
representation  of  non-Hodgkin  lymphoma  (NHL) 
versus  Hodgkin  lymphoma,  B-cell  lineage 
derivation, involvement of extranodal and unusual 
sites, aggressive histopathology, aggressive clinical 
behavior,  and  frequent  association  with  EBV 
infection.  Despite  these  common  features,  PTLD 
display a high degree of histogenetic and molecular 
heterogeneity
18-21. Early-onset  PTLD,  occurring 
within  1  year  after  transplantation,  are  mainly 
polyclonal  or  monoclonal  polymorphic  B-cell 
proliferations, frequently  associated  with  Epstein–
Barr virus (EBV) infection. Conversely, most late-
onset  PTLDs  are  monoclonal  lymphoid 
malignancies  carrying  EBV  infection  only  in  a 
fraction of cases
1-4,11,12.
Although  it  is  generally  assumed  that  most 
PTLD  occurring  after  solid  organ  transplantation 
arise  from  lymphoid  cells  of  the  recipient  (R-
PTLD),  an  increasing  number  of  case  reports 
suggest  that,  particularly  in  liver  transplant 
recipients,  a  considerable  fraction  of  PTLD  arise 
from donor B-cells (D-PTLD)
22. In liver transplant 
patients, D-PTLD and R-PTLD differ significantly 
for timing and clinical presentation. Generally, D-
PTLD  are  early-onset,  EBV-driven 
lymphoproliferations  that,  at  diagnosis,  are 
clinically and histologically confined to the hepatic 
hilum. On the contrary, R-PTLD are mainly late-
onset  lymphoproliferations  that,  at  diagnosis,  are 
widespread diseases with involvement  of multiple 
nodal and extranodal sites
22.
This  review  will  focus  on  the  molecular 
pathogenesis and histogenesis of PTLD occurring in 
patients  undergoing  solid  organ  transplantation, 
with special emphasis on the role of viral infection, 
cellular molecular lesions and antigen stimulation in 
the pathogenesis of the disease.
Molecular Pathogenesis of Ptld
Viral  infection: Oncogenic  viruses  known  to  be 
involved in PTLD pathogenesis include EBV and 
human herpesvirus type-8 (HHV-8). Both EBV and 
HHV-8  act  predominantly  through  direct 
mechanisms, i.e. the virus is able to directly infect 
the  tumor  clone  and  exerts  a  transforming  effect 
upon  B-cells.  Viral  infection  in  PTLD  exploits 
several  strategies  to  ensure  persistent  infection, 
namely  prevention  of  death  of  infected  cells, Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Figure 1. Morphology and phenotype of PTLD. (A) P-PTLD consisting mainly of small- and medium-sized lymphoid cells (Giemsa 
staining). (B) PTLD with diffuse large B cell morphology displaying the BCL6+/MUM1-/CD138- phenotypic pattern. Tumour cells 
show nuclear staining pattern with the anti BCL6 MoAb. (C) P-PTLD displaying the BCL-6-/MUM1+/CD138- phenotypic pattern. 
Most neoplastic cells show strong nuclear immunoreactivity with the anti MUM1 antibody. (Paraffin-embedded tissue sections, 
magnification x 400).
enhancement of their proliferation to maintain the 
infected  reservoir,  and  evasion  of  the  immune 
system
9,23-25.
EBV: Several lines of evidence suggest that EBV 
infection has a major  pathogenetic role in  PTLD. 
First, EBV infects 60-80% PTLD, including 100% 
early PTLD, and 80-100% post-transplant HL
24,25.
Second,  in  many  cases  of  monomorphic  PTLD, 
EBV  infection is  monoclonal,  consistent  with  the 
hypothesis  that  the  virus  has  been  present  in  the 
tumor  progenitor  cells  since  the  early  phases  of 
clonal expansion
18. Third, EBV infected B-cells are 
present in increased number in blood and tissues of 
patients  who  subsequently  develop  PTLD
26,27.
Furthermore, decrease of EBV-specific cytotoxic T-
cells  and  increase  in  EBV  viral  load  is  strongly 
associated  with  PTLD  development
28,29. Fourth, 
treatment  of PTLD with autologous  EBV-specific 
cytotoxic  T-cells  may  result  in  viral  load  control 
and  tumor  size  reduction
30. Finally,  several  viral 
genes  expressed  during  latent  infection  of  PTLD 
have transforming activity for B-cells
9,31-33.
EBV is a double strand DNA virus belonging to 
the -herpesvirus family that benignly infects over 
95%  of  the  human  population  for  life
31-33.  EBV 
targets B lymphocytes and, after acute infection, the 
virus DNA forms a circle and persists as an episome 
in the nuclei of resting memory B-cells establishing 
a  latent  infection
31-33.  In  latently  infected  B-cells, 
EBV encodes a series of viral proteins that interact 
with  or  exhibit  homology  to  a  variety  of  signal 
transducers,  cytokines  and  antiapoptotic  human 
molecules. These proteins are EBV nuclear antigens 
(EBNA)1,  EBNA2,  EBNA3A,  EBNA3B, 
EBNA3C,  EBNA-LP  and  the  latent  membrane 
protein (LMP)1, LMP2A and LMP2B. Beside these 
proteins,  EBV-encoded  non-translated  RNAs 
(EBER)  are  transcribed  in  latently  infected  B-
cells
31-33. Based on the pattern of expression of the 
latency genes, three types of latent infection have 
been described: i) latency I, that is defined by the 
expression of EBER and EBNA1; ii) latency II, that 
is  characterized  by  the  expression  of  EBER, 
EBNA1,  LMP1,  LMP2;  and  iii)  latency  III,  the 
“growth  program”,  denoted  by  the  expression  of 
EBER, all EBNAs, LMP1 and LMP2
31-33. In PTLD, 
all three latency programs may be observed.
EBNA1  is  a  DNA-binding  nuclear 
phosphorprotein, that is required for replication and 
maintenance  of  the  episomal  EBV  genome
31-33. 
EBNA1 is also a cis-acting inhibitor of MHC class 
I-restricted presentation and an inhibitor of antigen 
processing via the ubiquitin/proteosome pathway
34. 
Directing  EBNA1  expression  to  B  cells  in 
transgenic mice has been shown to result in B-cell 
lymphomas, suggesting that EBNA1 might have a 
direct  role  in  lymphomagenesis  cooperating  with 
MYC
35. 
EBNA2  is  a  transcriptional  coactivator  that 
regulates  both  viral  latency  genes,  for  example 
LMP1  and  LMP2,  and  many  cellular  genes 
involved  in  proliferation  and  survival,  including 
cMYC
31-33,36. EBNA2 does not bind directly to the 
DNA but interacts with other transcription factors, 
namely the  viral  transcription factor  Cp1  and  the 
cell  transcription  factor  RBP-Jk  involved  in  the 
NOTCH1 signaling pathway
37. This pathway is well 
known to  be  involved  in  lymphomagenesis,  since 
NOTCH1 is a proto-oncogene frequently activated 
by  mutation/translocation  in  T-cell  lymphoblastic 
lymphoma
38.
Two  main  types  (1  and  2)  of  EBV  are 
distinguished on the basis of sequence variation in 
the  EBNA  proteins. Although  type  2  EBV 
frequently  infects  immunosuppressed  individuals, 
no  clear  correlation  has  been  identified  between 
EBV strain and lymphoma development
39-44.Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Figure 2. The role of LMP1 in promoting survival in PTLD. LMP1 is a transmembrane protein consisting of a short N-terminal 
cytoplasmic  domain,  six  transmembrane-spanning  domains  and  a  C-terminal  cytoplasmic  domain.  LMP1  shares  no  significant 
overall homologies with any known cellular protein. The transmembrane domains of LMP1 have the intrinsic feature to oligomerize 
spontaneously within the plasma membrane. This autoaggregation of LMP1 molecules mimics the crosslinking of receptors of the 
TNF-R  family  induced  by  a  ligand  (e.g.  TNF-R1  by  TNFCD40 by CD40L). As a result, LMP1 is  constitutively  active 
independent of the binding of a ligand. Three subdomains in the cytoplasmic C-terminus of LMP1 (CTAR 1, 2, 3) serve as platforms 
for the binding of signalling molecules and for induction of signal transduction cascades. Both CTAR1 and CTAR2 participate in the 
induction of the anti-apoptotic transcription factor NF-kB. CTAR1 provides a docking site for TNF-R-associated factors (TRAFs). 
CTAR1 signalling induces the non-canonical NF-kB pathway via the NF-κB-inducing kinase (NIK) and the Inhibitory-kB Kinase 
(IKK) . CTAR2 does not bind TRAFs directly but triggers the classical NF-kB pathway through direct interaction with the TNF-R-
associated death domain protein (TRADD). TRADD, in the contest of TNF-R1 complex, normally signals cell death, whereas, in the 
context of LMP1, signals cell growth. Also the mitogenic c-Jun N-terminal kinase 1 (JNK1) / activator protein 1 (AP1) pathway is 
activated  by  LMP1.  AP1  is  a  dimer  of  JUN/JUN  or  JUN/FOS  proto-oncoproteins.  AP1  is  solely  triggered  at  CTAR2.  The 
JAK3/STAT signalling cascade, known to be involved in the control of cell proliferation, is triggered by the CTAR3 domain which is 
located between CTAR1 and CTAR2. It has been demonstrated that the p38 MAPK pathway is also induced by LMP1. p38 MAPK 
mediates cytokine induction by LMP1. 
LMP1 is the major transforming protein of EBV 
(Figure  2)
31-33.  LMP1  is  an  integral  membrane 
protein expressed on the surface of infected B-cells 
and  involved  in  transformation  by  acting  as  a 
constitutively active substitute for CD40, a receptor 
that  physiologically  provides  a  signal  for 
proliferation  and  survival  to  B-cells
45.  LMP1 
mimics  CD40  by  binding  the  same  cytoplasmic 
signal  transduction  molecules,  namely  the  tumor 
necrosis  factor  receptor  associated  factors 
(TRAFs)
46. TRAFs, in turns, activate at least four 
signaling pathways represented by NF-kB, c-Jun N-
terminal  kinase  1  (JNK1)  /  activator  protein  1 
(AP1), p38 mitogen-activated protein kinase and the 
JAK3/STAT  pathway.  These  molecules  affect 
diverse  signaling  cascades  that  lead  to  enhanced 
expression of B-cell adhesion molecules, activation 
markers, cMYC and the antiapoptotic factors BCL2 
and A20
47-50.
LMP1  appears  to  play  a  critical  role  in  the 
pathogenesis of PTLD derived from donor B-cells. 
In  a  recent  study  from  our  group
22,  all  D-PTLD 
associated with EBV infection expressed the viral
oncoproteins  EBNA2  and  LMP1.  Notably,  seven 
out of nine D-PTLD were infected by EBV variants 
with deletion of the carboxy terminus of LMP1. In 
particular,  five  cases  showed  the  69-LMP1 
variant, which was rarely detected in a consecutive Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
series  of  PTLD  from  the  same  geographical  area 
and  infrequently  found  in  the  Italian  population. 
LMP1-deleted  variants  have  been  reported  to  be 
associated with HIV-related Hodgkin’s lymphoma, 
whereas  association  with  PTLD  is  currently 
controversial
39-44.  The  high  prevalence  of  LMP1-
deleted variants in D-PTLD could be related to the 
higher  transforming  activity displayed  in  vitro  by 
these EBV variants
47. Nevertheless, it remains to be 
determined  whether  currently  unidentified 
recipient-related factors may have a role in favoring 
the  generation  of  D-PTLD  infected  by  LMP1-
deleted variants, like the inability of the recipient 
immune  system  to  recognize  and  destroy  B-cells 
expressing  LMP1  variants  that  potentially  lack 
some epitopes.
Other  EBV-encoded  genes,  though  not  strictly 
transforming,  may  also  be  involved  in 
lymphomagenesis
31-33.  LMP2A  is  an  integral 
membrane protein that contains an immunoreceptor 
tyrosine-based  activation  motif  (ITAM)  (Figure 
3)
51,52. This motif is similar to that present in B cell 
receptor (BCR) coreceptors CD79a and CD79b, and 
transmits activating signals after BCR stimulation. 
LMP2A binds and thus sequesters tyrosine kinases 
from  the  BCR,  resulting  in  inhibition  of  BCR 
signaling
51.  This  prevents  unwanted  antigen-
triggered activation of infected B-cells, that would 
otherwise cause entry into lytic cicle. On the other 
hand, LMP2A is also able to  stimulate the  BCR-
associated tyrosine kinases providing an important 
survival signal to B-cells
52. EBER1 and 2 are short 
strand non-coding RNAs expressed in all forms of 
latent  infection.  EBERs  seem  to  be  involved  in 
inducing autocrine IL-10 secretion by BL cells, that 
might  stimulate  growth  of  infected  neoplastic  B-
cells and suppress cytotoxic T-cells
53. In addition, 
EBERs  might  mediate  resistance  of  BL  cells  to 
interferon-α (IFNα)
54. 
Human  Herpes  Virus  8  (HHV-8): HHV-8  is  a 
double  strand  DNA  virus  belonging  to  the  -
herpesvirus  family.  Similar  to    EBV,  HHV-8 
establishes a lifelong latent infection in which the 
viral DNA persists as an episome in the nuclei of 
infected  cells
55,56.  HHV-8  infects  100%  primary 
effusion lymphomas (PEL) arising in transplanted 
patients
7,57.  A  number  of  HHV-8  genes  are 
homologous  to  human  genes  involved  in 
proliferation,  anti-apoptosis,  angiogenesis  and 
cytokines that are able to transform human cells in 
vitro and/or in vivo, and are potentially involved in 
lymphomagenesis
55,56.  Post-transplant  PEL  are 
characterized  by  latent  HHV-8  infection  and 
express  a  restricted  pattern  of  HHV-8  encoded 
genes
57,58.  HHV-8  encoded  latency-associated 
nuclear antigen 1 (LANA1) interacts with p53 and 
suppresses  the  p53  transcriptional  activity  and 
ability to induce apoptosis
59. Furthermore, LANA1 
binds  to  the  Rb  protein,  thus  releasing  the 
transcription  factor  E2F  that  upregulates  genes
involved  in  cell  cycle  progression
60.  Finally, 
LANA1  is  able  to  induce  expression  of  IL-6 
through interaction with AP1 transcription factor
61. 
The v-cyclin gene encodes a homologue of human 
cyclin  D2
62.  Similar  to  cyclin  D2,  v-cyclin 
contributes  to  Rb  phosphorrylation  by  activating 
cyclin-dependent  kinases. Phosphorylated Rb then 
releases  the  E2F  transcription  factor,  thus 
cooperating  with  LANA1  in  inducing  cell  cycle 
acceleration
62. In contrast to human cyclin D2, v-
cyclin is resistant to inhibition by p16, p21 and p27, 
a family of cyclin dependent kinase inhibitors that 
physiologically  block  cell  cycle  progression
63-65. 
Overall, v-cyclin permits to circumvent normal cell 
cycle  checkpoints,  and  leads  to  constitutive  cell 
cycling.
Simian  Virus  40  (SV40): The  involvement  of 
simian virus 40 (SV40) in PTLD pathogenesis has 
been  a  matter  of  recent  debate.  Based  on  the 
paradigm of other lymphoma-related viruses, SV40 
displays  several  features  predicting  a  putative 
pathogenetic  role.  Although  two  initial  reports 
described  a  high  prevalence  of  SV40  in  NHL, 
including  immunodeficiency-related  NHL,  the 
association between SV40 and PTLD and, more in 
general,  NHL  has  been  subsequently  denied  by 
large  molecular,  immunohistochemical  and 
serological studies
66-70.
Hepatitis C Virus (HCV): Several epidemiological 
studies  and  meta-analysis  have  underlined  the 
association between HCV infection and NHL in the 
immunocompetent  host.  The  current  pathogenetic 
hypothesis  holds  that  HCV  may  act  on  B-cells 
indirectly  through  chronic  antigen  stimulation,  as 
suggested by the identification of molecular clues of 
antigen stimulation in HCV-related NHL and by the 
expression  of  HCV  specific  IGV  in  a  fraction  of 
HCV-related NHL
71. Although there are a number 
of  case  reports  of  PTLD  occurring  in  patients 
positive for HCV, few studies have investigated the 
relationship  between  HCV  and  PTLD 
systematically, and the results are conflicting
72-74.
Molecular alteration of cellular genes:  Infection 
by oncogenic viruses is a pathogenetic mechanism 
often  necessary,  but  not  sufficient  to  develop 
monoclonal  PTLD.  Progression  to  lymphoma 
requires the accumulation of genetic or epigenetic Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Figure 3. Signalling relationship between LMP2A and the BCR. LMP2A consists of cytoplasmic amino-terminal and carboxy-
terminal domains linked by 12 transmembrane sequences with no significant extracellular domain. The amino-terminal domain of 
LMP2A contains the same immunoreceptor tyrosine-based activation motifs (ITAMs) found in the α- and β-chains of the B-cell 
receptor (BCR). Both LMP2A and the BCR associate with LYN, a member of the Src family of tyrosine kinases. Phosphorylation of
tyrosine residues within the ITAM by LYN leads to recruitment of the SYK tyrosine kinase and the canonical downstream BCR 
signalling events. LMP2A signalling does not cause B cells to grow, but delivers the tonic signal that is essential for the survival of 
all B cells. BLNK, B-cell linker protein; DAG, diacylglycerol; [Ca2+], intracellular Ca2+; IP3, inositol-1,4,5-trisphosphate; PI3K, 
phosphatidylinositol 3-kinase; PLC-γ2; phospholipase C-γ2; PKC, protein kinase C; Yp, phoshorylated tyrosine.
alterations  of  cellular  genes.  At  variance  with 
lymphoma  arising  in  immunocompetent  hosts, 
whose  genome  is  relatively  stable,  a  fraction  of 
PTLD are characterized by microsatellite instability 
as  a  consequence  of  defects  in  DNA  mismatch 
repair mechanisms
75. These cases are characterized 
by  a  mutator  phenotype,  thus  accumulating 
mutations  in  several  genes  including  the 
proapoptotic factors BAX and CASPASE 5, and the 
DNA repair gene RAD50. The explanation to why 
PTLD and other types of immunodeficiency-related 
lymphoma  display  a  mutator  phenotype,  that  is 
otherwise  rarely  observed  in  NHL  of 
immunocompetent hosts, remains speculative. One 
hypothesis  is  that  the  mutator  phenotype  may 
generate  numerous  neoantigens  at  the  tumor  cell 
surface  as  a  consequence  of  mutations  affecting 
various genes. In the context of immunodeficiency, 
the host  immune  system  might  be  less  prone  to 
recognize and eliminate such highly immunogenic 
lymphoma  cells.  Apart  from  microsatellite 
instability,  molecular  alterations  of  cellular  genes 
recognized in PTLD include alterations of cMYC, 
BCL6,  p53,  DNA  hypermethylation,  and  aberrant 
somatic hypermutation
76. 
cMYC: Analogous  to  BL  arising  in 
immunocompetent  or  HIV-infected  hosts, 
chromosomal  breaks  at  8q24  are  found  in  100% 
post-transplant  BL
5,7.  Chromosomal  translocations 
cause cMYC deregulation by at least two distinct 
mechanisms
76. First, translocated cMYC alleles are 
juxtaposed  to  heterologous  regulatory  elements 
derived  from  Ig  loci
76.  Second,  the  regulatory 
regions  of  cMYC  are  consistently  affected  by 
structural  alterations  that are  supposed  to  modify 
their  responsiveness  to  cellular  factors  regulating 
cMYC  expression
76.  Oncogenic  conversion  of 
cMYC also stems from amino acid substitutions in 
cMYC exon 2
76. These mutations affect the amino-
terminal  transcriptional  activation  domain  of  the 
gene  and  allow  escape  from  the  p107-mediated 
modulation  of  the  cMYC  transactivator  domain. Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
The cMYC proto-oncogene promotes proliferation 
through  different  mechanisms,  that  include 
upregulation of genes involved in cell cycle control, 
downregulation of growth arrest genes, activation of 
telomerase reverse transcriptase (TERT), induction 
of  protein  kinase  A  and  increase  of  lactate 
dehydrogenase-A gene, whose product participates 
in normal anaerobic glycolysis and is necessary for 
the growth of a cell mass with an hypoxic internal 
microenvironment
77-79.
BCL6: BCL6  is  a  transcriptional  repressor 
containing the POZ domain that is homologous to 
domains  found  in  several  other  zinc-finger 
transcription  factors
76.  BCL6  is  needed  for  GC 
development  and  survival,  whereas  its 
downregulation  may  be  necessary  for  further 
differentiation of B-cells. Rearrangements of BCL6 
are  found  in  20–40%  of  DLBCL  of 
immunocompetent  hosts  and  HIV-DLBCL,  but 
seldom occur in PTLD
80. Conversely, in about 50% 
PTLD, the BCL6 gene is affected by multiple, often 
biallelic,  mutations  introduced  by  the  SHM 
mechanism  that  selectively  cluster  within  the 
noncoding  regions  of  the  gene
21,81.  The  DNA 
sequences most frequently affected by mutations lie 
near  the BCL6 promoter region and overlap with 
the major cluster of chromosomal breaks at 3q27, 
suggesting that mutations and rearrangements may 
be selected for their ability to alter the same region, 
which, conceivably, regulates the normal expression 
of BCL6
82. 
TP53: Mutations of TP53 are detected in a fraction 
of post-transplant DLBCL
18. Missense mutations of 
TP53 usually result in the inability to transactivate 
its  target  genes,  and  downregulate  expression  of 
p21,  a  cyclin  kinase  inhibitor  that  neutralizes  the 
activity of cyclin E
76. 
Aberrant  DNA  methylation: Aberrant 
hypermethylation  of CpG islands  is  an epigenetic 
alteration  that  causes  repression  of  gene 
transcription and represents a mechanism for tumor 
suppressor  gene  inactivation  alternative  to 
mutations/deletions
83.  Aberrant  promoter 
hypermethylation  has  been  documented  as  a 
relevant  mechanism  of  lymphomagenesis  in 
transplanted  patients,  targeting  multiple  and 
functionally  heterogeneous  lymphoma-related 
genes
84.  Hypermethylation  of  O6-methylguanine-
DNA  methyltransferase  (MGMT)  targets 
approximately 60% monomorphic PTLD
84. MGMT 
is a DNA repair gene that removes mutagenic and 
cytotoxic  adducts  introduced  in  the  DNA  from 
environmental  and  therapeutic alkylating  agents
85. 
The potential role of MGMT in lymphoma stems 
from  the  fact  that  MGMT  inactivation  favors 
lymphomagenesis  in  knockout  mice.  Consistent 
with  the  protective  function  of  MGMT  against 
spontaneous  and  alkylator-induced  G  to  A 
transitions  in  human  DNA,  MGMT  inactivation 
may cause tumors by generating genetic instability 
and acquisition of p53 and RAS point mutations
85. 
Hypermethylation  of  death-associated  protein 
kinase  (DAP-k)  occurs  in  75%  monomorphic 
PTLD
84. DAP-k is a pro-apoptotic serine-threonine 
kinase  involved  in  the  extrinsic  pathway  of 
apoptosis initiated by INF, TNF and Fas ligand
86. 
In addition, DAP-k also counteracts cMYC induced 
transformation by activating the p53 checkpoint and 
favoring cMYC induced apoptosis
86. Consequently, 
inactivation of DAP-k prevents apoptosis triggered 
by  death  receptors  and  weakens  the  apoptotic 
response secondary to  cMYC activation. The p73 
gene is a candidate tumor suppressor gene sharing 
structural  and  functional  similarity  with  p53  and 
involved  in  cell  cycle  control  and  apoptosis. 
Hypermethylation  of p73 occurs in  approximately 
20% PTLD
84. 
Aberrant  somatic  hypermutation: Normally,  the 
somatic hypermutation (SHM) process targets IGV 
genes of GC B-cells
87. In over half of DLBCL, the 
SHM  process  appears  to  misfire  and  aberrantly 
target  multiple  proto-oncogenes  implicated  in  the 
pathogenesis  of  lymphoid  malignancies  (PIM1, 
PAX5, RhoH/TTF and cMYC)
88. PIM1 encodes a 
serine-threonine kinase and is occasionally involved 
in  DLBCL  associated  chromosomal 
translocations
89;  PAX5  encodes  a  B-cell  specific 
transcription  factor  essential  for  B-lineage 
commitment  and  differentiation  and  involved  in 
translocations in about 50% of lymphoplasmacytic 
lymphoma
90;  RhoH/TTF  encodes  a  small  GTP-
binding protein belonging to the RAS superfamily 
and  is  involved  in  rare  instances  of  lymphoma 
translocations
91. Mutations affecting PIM1, PAX5, 
RhoH/TTF  and  cMYC  recapitulate  the  molecular 
features  of  physiological  SHM,  but  they  do  not 
occur at a significant level in normal GC B-cells, 
suggesting a malfunction of SHM associated with 
DLBCL
88.  On  these  basis,  this  phenomenon  has 
been  termed  aberrant  SHM
88.  In  PTLD,  aberrant 
SHM is not restricted to DLBCL, and appears to be 
involved  in  the  pathogenesis  of  lymphomas 
originating  from  both  recipient  and  donor  B-
cells
22,92.  Based  on  the  distribution  and  type  of 
mutations, aberrant SHM may alter the function of 
PIM1,  PAX5,  RhoH/TTF  and  cMYC  with  two 
modalities
89-91.  First,  because  mutations  cluster 
around the gene  regulatory regions, mutations may Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Figure 4. Pathogenetic model of post-transplant lymphoproliferative disorders. (A) The somatic hypermutation process (SHM) 
affecting the immunoglobulin variable region genes within the germinal centre is aimed at increasing the affinity of the B-cell 
receptor (BCR)  for the antigen. (B) B-cells that have successfully undergone affinity maturation for the antigen  are positively 
selected and rescued from apoptosis. (C) On the contrary, B-cells failing this process are induced to apoptosis. (D) A relevant 
fraction of post-transplant lymphoproliferative disorders (PTLD) fail to express the BCR, mainly due to crippling mutations of 
immunoglobulin  genes  introduced  by  the  SHM  process,  and  thus  are  predisposed  to  programmed  cell  death.  The  putative 
mechanisms that rescue PTLD from apoptosis are represented by LMP1 expression and/or molecular lesions affecting genes that 
regulate apoptosis.
deregulate gene transcription. Second, a subset of 
mutations of cMYC and PIM1 lead  to  aminoacid
substitutions,  and,  consequently,  may  alter  the 
biochemical  and/or  structural  properties  of  the 
protein. 
Antigen stimulation: Clues of the pathogenetic role 
of  antigen  stimulation  may  be  derived  from  the 
molecular features of IGV genes utilized by B-cell
lymphoma
93,94.  Among  immunodeficiency-related 
lymphomas, HIV-related non-Hodgkin lymphomas 
(HIV–NHL)  provide  an  example  of  antigen 
stimulation  in  disease  pathogenesis
95.  The 
pathogenetic role of antigen stimulation in PTLD is 
less evident, since 50% PTLD derive from B-cells 
that have lost the ability to express a functional B-
cell  receptor  (BCR)
20,21,96-98.  A  frequent  cause  of 
BCR  inactivation  in  PTLD  is  represented  by 
crippling  mutations  of  IGV  genes,  that  are 
generated by the SHM process and introduce stop 
codons in originally in-frame rearrangements
20,21,96-
98.  Since  the  expression  of  a  functional  BCR  is 
crucial for B-cell survival, PTLD lacking BCR are 
thought  to  acquire the  ability  to  escape  apoptotic 
death in the absence of antigen stimulation
20,21,96,97. 
EBV infection has been proposed as a mechanism 
of  apoptotic  rescue  in  PTLD  with  non-functional 
BCR,  although  other  mechanisms  might  also  be 
involved (Figure 4). 
Among the 50% PTLD displaying a functional 
BCR,  molecular  signs  of  antigen  stimulation  are 
documented  in  a  fraction  of  cases.  In  fact, 
approximately  60%  PTLD  with  functional  BCR 
select mutations in order to maintain intact the IGV 
framework  region  structure,  and  30%  select Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Figure 5.  Model  of PTLD histogenesis based on  the expression of the phenotypic markers BCL6,  MUM1 and CD138. The 
majority of PTLD, namely diffuse large B-cell lymphoma showing immunoblastic morphology (DLBCL-IB) and polymorphic PTLD 
(P-PTLD),  carry  the  BCL6-/MUM1+/CD138- profile,  denoting  a  late  centrocyte  origin.  A  fraction  of  DLBCL-IB  are  BCL6-
/MUM1+/CD138+, denoting an immunoblastic-plasmablastic origin. Burkitt/Burkitt like lymphoma (BL/BLL) and diffuse large B-
cell lymphoma with centroblastic morphology (DLBCL-CB) are BCL6+/MUM1-/CD138-, denoting a centroblast-centrocyte origin.
mutations  to  increase  antigen  binding  affinity
20,98. 
Overusage  of  specific  IGV  genes  known  to  be 
involved in autoimmune phenomena, as observed in 
HIV–NHL,  does  not  appear  to  be  a  distinctive 
feature  of  PTLD
98.  IGV  mutations  generated  by 
SHM  may introduce  new  sites  of  oligosaccharide 
linkage  on  the  Ig  protein
99.  In  the 
immunocompetent  host,  this  phenomenon  is 
specific  for  B-NHL  derived  from  GC  cells
99. 
Glycosylation may alter the biochemical properties 
of the Ig by enhancing or reducing the affinity for 
antigen. Furthermore, it might activate the BCR in 
an  antigen  independent  way  by  mediating  the 
interaction  with  lectins  of  the  microenvironment. 
Despite  their  origin  from  GC  B-cells,  and  at  a 
variance with HIV–NHL, the acquisition of novel 
sites  of  IGV  glycosylation  is  a  rare  event  in 
PTLD
100.  This  observation  is  consistent  with  the 
hypothesis  that  BCR  stimulation  does  not  play  a 
major pathogenetic role in many PTLD. 
Molecular Histogenesis Of Ptld: The histogenesis 
of PTLD has been elucidated by the application of a 
model exploiting genotypic and phenotypic markers 
and allowing the distinction of mature B-cells into 
different  compartments,  namely  virgin  B-cells, 
germinal centre (GC) B-cells and post-GC B-cells 
(Figure 5)
20-21,100. The most informative genotypic 
marker is represented by SHM of immunoglobulin 
variable  (IGV)  genes,  that  takes  place  in  the  GC 
microenvironment
87.  Positivity  for  IGV  SHM 
indicates that a given B-cell tumor derives from GC 
or post-GC B-cells. The presence of ongoing IGV 
mutations,  documented  by  intraclonal 
heterogeneity,  indicates  that  the  lymphoma  clone 
reflects centroblasts experiencing the GC reaction, 
whereas  absence  of  intraclonal  heterogeneity 
suggests derivation  from late  centrocytes or post-
GC B-cells that have terminated the GC reaction
87. 
Phenotypic  markers  of  histogenesis  include  the Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
BCL6, MUM1, and CD138 proteins, and contribute 
to  the  distinction  between  GC  and  post-GC  B-
cells
101-104.  Expression  of  BCL6  clusters  with  the 
GC  stage  of  differentiation,  MUM1  positivity 
clusters with B-cells exiting the GC and with post-
GC B cells, and CD138 is a marker of pre-terminal 
B-cell  differentiation
101-104.  Application  of  this 
histogenetic  model to  PTLD  arising  after  solid 
organ transplantation has revealed that: (i) 25% P-
PTLD  and  10%  DLBCL  carry  unmutated  IGV 
genes, denoting a pre-GC origin; (ii) 100% BL and 
25% DLBCL, mainly of centroblastic morphology, 
carry  ongoing  IGV  mutations,  denoting  an origin 
from GC centroblasts; (iii) 75% P-PTLD and 65% 
DLBCL  carry  stable  IGV  mutations,  denoting  a 
centrocyte  or  post-GC  origin
20,21,98.  The  fact  that 
IGV mutations occur in the overwhelming majority 
of PTLD documents that malignant transformation 
targets GC  B-cells  and  their  descendants  both  in 
Epstein-Barr  virus  (EBV)–positive  and  EBV–
negative cases
20,21,96-98. These same cellular subsets 
also  give  rise  to  most  B-cell  lymphomas  in 
immunedeficiency  settings  other  than  post-
transplant,  including  AIDS  and  primary 
immunodeficiencies
95,105.  The  few  PTLD  lacking 
IGV SHM tend to arise early after transplantation, 
consistently carry EBV infection, mimic a post-GC 
phenotypic profile, and may derive from truly pre-
GC B-cells or, alternatively, from B-cells that have 
transited through the GC but have been impaired in 
exerting  a full GC-reaction
87,101-104.  Among PTLD 
deriving from GC-experienced B-cells, analysis of 
phenotypic markers of histogenesis identifies three 
predominant profiles of the disease (Figures 1 and
5)
21.  PTLD  belonging  to  the  first  histogenetic 
category  express  the  BCL6+/  MUM1+/-/CD138-
profile and reflect B-cells actively experiencing the 
GC reaction. These PTLD associate with ongoing 
SHM and are morphologically classified as DLBCL 
centroblastic  or  as  BL
21.  A  second  category  of 
PTLD  reflects  the  BCL6-/MUM1+/CD138-
phenotype  and  comprises  65%  P-PTLD and  30% 
DLBCL,  mainly  with  immunoblastic  features
21. 
This PTLD subset putatively derives from B-cells 
that have concluded the GC reaction but have not 
yet undergone terminal differentiation. The BCL6-
/MUM1+/CD138- profile is common among PTLD, 
but  is  rare  among  HIV-related  lymphomas, 
underscoring  biological  differences  between  these 
two  groups  of  immunodeficiency-related 
lymphomas
21,101.  A  third  group  of  PTLD  is 
reminiscent  of  post-GC  and  pre-terminally 
differentiated  B-cells  and  show  the  BCL6-
/MUM1+/CD138+ phenotype and, if EBV positive, 
express  the  LMP1  antigen
21.  These  PTLD  are 
morphologically  represented  by  either  P-PTLD 
(35%  of  cases)  or  DLBCL  immunoblastic.  The 
BCL6-/MUM1+/CD138+  histogenetic  profile  is 
shared also by many HIV-related lymphomas
101. 
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